Why I voted "No" to Truvada PrEP

Annals of Internal Medicine

Volumn 157, Issue 7, 2012, Pages 519-520

  Wood, Lauren V ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;

ANUS INTERCOURSE; BODY WEIGHT; CONDOM; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HETEROSEXUALITY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LONG TERM CARE; NEPHROTOXICITY; NOTE; PATIENT COMPLIANCE; PATIENT COUNSELING; PREEXPOSURE PROPHYLAXIS; PREVENTIVE MEDICINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SEXUALITY; UNITED STATES; VIRUS TRANSMISSION;

EID: 84868321590     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-157-7-201210020-00511     Document Type: Note

References (10)

1. Centers for Disease Control and Prevention. HIV in the United States: at a glance. March 2012. Accessed at www.cdc.gov/hiv/resources/factsheets/us.htm on July 7, 2012.
2. U.S. Food and Drug Administration. Slides for the May 10, 2012 Antiviral Drugs Advisory Committee (AVDAC) Meeting [Slide 10]. Accessed at www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugs AdvisoryCommittee/ucm305776.htm on July 7, 2012.
3. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587-99. [PMID: 21091279]
4. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al; the Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012. [PMID: 22784037]
5. U.S. Food and Drug Administration. Briefing information for the May 10, 2012 meeting of the Antiviral Drugs Advisory Committee. Accessed at www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugs AdvisoryCommittee/ucm303212.htm on July 7, 2012.
6. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al; the FEM-PrEP Study Group. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411-22. [PMID: 22784040]
7. Jullien V, Tréluyer JM, Rey E, Jaffray P, Krivine A, Moachon L, et al. Population pharmacokinetics of tenofovir in human immunodeficiency virusinfected patients taking highly active antiretroviral therapy. Antimicrob Agents Chemother. 2005;49:3361-6. [PMID: 16048948]
8. Gagnieu MC, Barkil ME, Livrozet JM, Cotte L, Miailhes P, Boibieux A, et al. Population pharmacokinetics of tenofovir in AIDS patients. J Clin Pharmacol. 2008;48:1282-8. [PMID: 18779377]
9. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al; the TDF2 Study Group. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012. [PMID:22784038]
10. Scherzer R, Estrella M, Li Y, Choi AI, Deeks SG, Grunfeld C, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26:867-75. [PMID: 22313955]